Pirfenidone is an anti-fibrotic medication primarily used to treat idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and loss of lung function. By modulating the activity of growth factors and cytokines, Pirfenidone reduces lung inflammation and fibrosis, thereby slowing disease progression. Common side effects may include nausea, fatigue, and diarrhea. In essence, Pirfenidone plays a vital role in managing IPF and improving patients' quality of life.
Pirfenidone inhibits the synthesis and activity of pro-fibrotic growth factors and cytokines, thereby reducing fibroblast proliferation and collagen deposition in lung tissue.